• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Zymeworks Inc. - Common Stock (NQ: ZYME )

    14.28 +0.14 (+0.99%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 664,439
    Open 14.30
    Bid (Size) 12.40 (1)
    Ask (Size) 14.26 (5)
    Prev. Close 14.14
    Today's Range 13.57 - 14.40
    52wk Range 7.970 - 17.70
    Shares Outstanding 57,771,204
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)
    Via Benzinga
    Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
    From Zymeworks Inc.
    Via GlobeNewswire

    Performance

    YTD
    +37.57%
    +37.57%
    1 Month
    +0.56%
    +0.56%
    3 Month
    +11.91%
    +11.91%
    6 Month
    +70.00%
    +70.00%
    1 Year
    +33.71%
    +33.71%

    More News

    Read More
    In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
    Via Benzinga
    FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
    Via Benzinga
    Exposures Product Safety
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    What Analysts Are Saying About Zymeworks Stock
    Via Benzinga
    FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
    From Zymeworks Inc.
    Via GlobeNewswire
    Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
    From Zymeworks Inc.
    Via GlobeNewswire
    Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
    Via Talk Markets
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.